News headlines about Axsome Therapeutics (NASDAQ:AXSM) have been trending positive on Friday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Axsome Therapeutics earned a news impact score of 0.27 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.4684472420632 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Several brokerages have commented on AXSM. Zacks Investment Research lowered Axsome Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, March 13th. ValuEngine raised Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $16.90.
Shares of AXSM opened at $2.35 on Friday. Axsome Therapeutics has a one year low of $2.05 and a one year high of $6.45. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.90 and a quick ratio of 2.90.
TRADEMARK VIOLATION WARNING: “Axsome Therapeutics (AXSM) Getting Favorable News Coverage, Report Finds” was posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/06/axsome-therapeutics-axsm-receiving-favorable-press-coverage-report-shows/2030406.html.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The company's product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and Alzheimer's disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.